In collaboration with Imperial College London, DNAe has been awarded a UK Knowledge Transfer Partnership (KTP) by Innovate UK to support the development of its Next Generation Sequencing (NGS) -based diagnostic platform for use in cancer surveillance.
The KTP program connects innovative companies with academic experts who can help them deliver their ideas. This award formalizes a collaboration between DNAe and Professor Charles Coombes, professor of medical oncology at Imperial Oil. KTP’s work will build on the existing research partnership between Professor Coombes and Professor Jacqui Shaw, Head of the Department of Genetics and Genome Biology and Professor of Translational Cancer Genetics at the University of Leicester.
The objective of the program is to develop a “liquid biopsy” test based on DNAe’s proprietary “sample-to-response” NGS technology, to directly detect and identify biomarkers and mutation hotspots that have been identified in research of Professors Coombes and Shaw. This will allow these markers to be used to monitor treatment and detect early recurrence of breast cancer. Under the terms of the partnership, a postgraduate researcher (the KTP associate) will be based at DNAe to integrate the expertise of the academic partners into the development of the test.
Samuel Reed, CEO of DNAe, said: “Recognizing that October is Breast Cancer Awareness Month, we are delighted to officially announce our collaboration with global experts Professors Coombes and Shaw, who bring their knowledge study of the use of circulating tumor DNA to manage the treatment of breast cancer. With this KTP award, we will be able to harness this deep expertise and combine it with our proven diagnostic technology. ”
DNAe’s integrated sequencing-based technology will bring genomic analysis to the point of need, allowing tests to move out of specialized labs and come closer to the patient. By detecting and sequencing tumor DNA directly from raw blood samples within hours, the DNAe platform has the potential to expose unresponsive or recurrent cancer earlier.
Professor Charles Coombes, Professor of Medical Oncology, Imperial, and Honorary Consulting Medical Oncologist, Imperial College Healthcare Trust, said: “Cancer surveillance is an essential part of successful treatment. First, we need to make sure that a patient’s tumor responds to treatment, and second, patients in remission need to be monitored for any signs of recurrence. Current surveillance options are slow, and any delay in appropriate cancer care can reduce the chances of survival and increase the problems and costs associated with treatment. Although we are in the early stages, I believe that DNAe’s integrated sequencing-based platform could ultimately deliver rapid, actionable information that would save patients’ lives.
Professor Jacqui Shaw, Head of the Department of Genetics and Genome Biology at the University of Leicester, added: “This is an exciting collaboration with DNAe and Imperial, where we will combine our expertise to develop a platform. rapid integrated liquid biopsy form for the management of breast cancer patients. ”